The goal of this project is to continue the development of a center at the University of Alabama (UAB) for brain tumor research which was started in 1992 with the awarding of a Brain Tumor Program Project Feasibility Grant. In this resubmission, the emphasis remains on studies of the cellular and molecular biology of malignant glial tumors. The revised Program consists of three laboratory-based Projects and an Administrative Core, which will handle the management of the program and facilitate interactions among group members. Project #1 (Dr. Etty N. Benveniste, Project Leader) will investigate the effects of several glioma-active cytokines on the expression of intercellular adhesion molecule-1 (ICAM1). Studies will focus on the role of the cytokine TGFbeta in suppressing ICAM-1 expression by gliomas, an effect which may allow these tumors to escape immune surveillance. Project #2 (Dr. Candece L. Gladson, Project Leader) will investigate the effects of platelet- derived growth factor (PDGF) on the expression and activity of glioma- derived, vitronectin-binding integrins. Studies will focus on the effects of PDGF on vitronectin-binding, internalization, and degradation, and on structure/function relationships of glioma-expressed integrins. Project #3 (Dr. Steven S. Rosenfeld,Project Leader) will investigate the role of myosin II in glioma invasiveness and angiogenesis. Biophysical and pharmacologic studies will be utilized to design methods of specifically interfering with myosin Ii function. These studies will give a clearer understanding of how myosin II function is regulated and will define parameters that may eventually be utilized in designing new, anti- invasive and anti-angiogenesis therapies. Collaborative interactions between each of the investigators, which were initiated by the awarding of P20 NS 31096, will continue in this Program Project. Taken together, these projects should lead to a better understanding of the cell biology of malignant glial tumors.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Program Projects (P01)
Project #
5P01NS034856-02
Application #
2655520
Study Section
Neurological Disorders Program Project Review A Committee (NSPA)
Program Officer
Jacobs, Tom P
Project Start
1997-03-15
Project End
2002-01-31
Budget Start
1998-02-01
Budget End
1999-01-31
Support Year
2
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of Alabama Birmingham
Department
Neurology
Type
Schools of Medicine
DUNS #
004514360
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Rosenfeld, Steven S; Xing, Jun; Chen, Li-Qiong et al. (2003) Myosin IIb is unconventionally conventional. J Biol Chem 278:27449-55
Choi, Chulhee; Gillespie, G Yancey; Van Wagoner, Nicholas J et al. (2002) Fas engagement increases expression of interleukin-6 in human glioma cells. J Neurooncol 56:13-9
Rosenfeld, S S; Jefferson, G M; King, P H (2001) ATP reorients the neck linker of kinesin in two sequential steps. J Biol Chem 276:40167-74
Oh, J W; Drabik, K; Kutsch, O et al. (2001) CXC chemokine receptor 4 expression and function in human astroglioma cells. J Immunol 166:2695-704
Han, X; Stewart Jr, J E; Bellis, S L et al. (2001) TGF-beta1 up-regulates paxillin protein expression in malignant astrocytoma cells: requirement for a fibronectin substrate. Oncogene 20:7976-86
Dong, Y; Benveniste, E N (2001) Immune function of astrocytes. Glia 36:180-90
Ma, Z; Qin, H; Benveniste, E N (2001) Transcriptional suppression of matrix metalloproteinase-9 gene expression by IFN-gamma and IFN-beta: critical role of STAT-1alpha. J Immunol 167:5150-9
Lee, S J; Drabik, K; Benveniste, E N (2001) Cloning of rat calcium-modulating cyclophilin ligand. DNA Seq 12:209-13
Xing, J; Wriggers, W; Jefferson, G M et al. (2000) Kinesin has three nucleotide-dependent conformations. Implications for strain-dependent release. J Biol Chem 275:35413-23
Gladson, C L; Stewart, J E; Olman, M A et al. (2000) Attachment of primary neonatal rat astrocytes to vitronectin is mediated by integrins alphavbeta5 and alpha8beta1: modulation by the type 1 plasminogen activator inhibitor. Neurosci Lett 283:157-61

Showing the most recent 10 out of 20 publications